focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,138.00
Bid: 12,138.00
Ask: 12,142.00
Change: -28.00 (-0.23%)
Spread: 4.00 (0.033%)
Open: 12,186.00
High: 12,198.00
Low: 12,114.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-India's Omicron cases mild, vaccine boosters not a priority -government

Fri, 10th Dec 2021 12:53

(Adds details)

NEW DELHI, Dec 10 (Reuters) - India has detected 25 cases of
the emergent Omicron variant of the coronavirus and all have
shown mild symptoms, the health ministry said on Friday, adding
that there was no immediate plan to authorise vaccine boosters.

Vaccine supplies have surged in India in recent months
thanks to the Serum Institute of India (SII), which now plans to
halve the monthly output of its version of the AstraZeneca
vaccine as demand has crashed.

The SII and other Indian drugmakers such as Dr. Reddy's
Laboratories, which distributes Russia's Sputnik
vaccine, have lobbied the government https://www.reuters.com/world/india/indian-vaccine-makers-bank-boosters-demand-crashes-2021-12-08
to approve booster shots in a bid to lift sales.

Senior health official Vinod Kumar Paul told a news briefing
that government experts were studying data on boosters but "our
emphatic view...is to (first) cover every adult with (just) the
primary two doses."

The government has said this target can be achieved by
January.

India has not considered authorising booster doses yet as
many in the country have been naturally infected and the
government believes two vaccine doses offer sufficient
protection for now, three informed sources told Reuters late
last month.

Around 87% of India's adults, estimated at 939 million
people, have received at least one dose of a vaccine and 54% of
them have received the full two. Inoculations for those under
the age of 18 years have not started.

Paul spoke after the World Health Organization recommended
that people with compromised immunity or those who received an
inactivated vaccine should receive a booster.

Inactivated vaccines, which use killed or inactivated
coronavirus to induce immunity, is made by India's Bharat
Biotech and some Chinese companies.

At 144 million doses, Bharat Biotech's Covaxin accounts for
about 11% of the total vaccine doses administered in India. Many
Indian healthcare workers received Covaxin early this year and
some experts say they should soon be allowed to take a booster.

India's daily new COVID-19 cases have hovered around 10,000
for the past few weeks, taking the total to 34.67 million, more
than 474,000 of whom have died.

Most contracted the Delta variant, though Omicron has spread
to five states after India's first two cases were reported on
Dec. 2. "All detected cases have mild symptoms," a health
ministry statement said.
(Reporting by Krishna N. Das, Rama Venkat and Sumit Khanna;
Editing by Mark Heinrich)

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.